Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 15/20 | 0.68 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | FNTA | P49354 | 2/20 | 0.52 |
| ▸ | FNTB | P49356 | 2/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9258097 | 0.88 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7505069 | 0.84 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7083825 | 0.82 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7480675 | 0.81 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL10588300 | 0.81 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| Hydrochloric Acid SCHEMBL6925307 | 0.81 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL3630524 | 0.81 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7507201 | 0.81 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL1064258 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL2786255 | 0.80 | CYP11B1 (0.71) | CYP11B1CYP11B2CYP19A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | claimed |
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | LES LABORATOIRES SERVIER (FR) | 2002-10-24 | — | — | US | disclosed |
| WO-2002057257-A1 | CYCLO`C!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREFOR | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057258-A1 | CYCLO`D!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
| EP-1225170-A2 | Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier S.A. (FR) | 2002-07-24 | — | — | EP | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | COASY, FNTA, FNTB | CYP11B1 147/4885CYP11B2 399/4885CYP19A1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.